Personal Information
Entreprise/Lieu de travail
Greater Boston Area United States
Profession
President & CSO at Aleta Biotherapeutics
Secteur d’activité
Medical / Health Care / Pharmaceuticals
Site Web
http://www.sugarconebiotech.com
À propos
I am a top-tier Biotechnology Investigator and Executive with extensive strategic and leadership experience and demonstrated success in bench to IND development of small molecule and biologic drugs for oncology, autoimmunity, chronic inflammation and fibrosis. I have deep experience in therapeutic area analysis and strategic development, opportunity assessment, due diligence, and alignment of research, commercial and clinical strategies. My recent accomplishments include working intensively with CoStim Pharmaceuticals' executive team to prioritize and launch that company's Cancer Immunotherapeutics portfolio. More recently I embedded with X-Chem Inc to create X-Rx Discovery, an asset-cent...
Mots-clés
immunotherapy
oncology
ido
car-t cells
adoptive cell therapy
tumor microenvironment
tim3
nivolumab
ipilimumab
cancer
pd-1
tumors
tregs
lymphoma
leukemia
ctla4
immunotherapeutics
biologic
clinical trials
cd20
cd19
biotech
biotechnology
solid tumors
r&d
#miceareliars
hdac
beta catenin
tgf beta
checkpoint inhibitor
a2ar
sting
aletabio.com
impact(tm)
cellular therapy
car t cells
adoptive cellular therapy
colorectal cancer
hyaluronan
pancreatic cancer
csf1r
mdsc
tam
ovarian cancer
pembrilizumab
tgfbeta
lag3
tnfr
pembrilizumab
lag3
tgfbeta
tnfr
pembrilizumab
lag3
tgfbeta
tnfr
tnfr
lag3
pembrilizumab
pd-1 family
b7 family
Tout plus
Présentations
(10)Personal Information
Entreprise/Lieu de travail
Greater Boston Area United States
Profession
President & CSO at Aleta Biotherapeutics
Secteur d’activité
Medical / Health Care / Pharmaceuticals
Site Web
http://www.sugarconebiotech.com
À propos
I am a top-tier Biotechnology Investigator and Executive with extensive strategic and leadership experience and demonstrated success in bench to IND development of small molecule and biologic drugs for oncology, autoimmunity, chronic inflammation and fibrosis. I have deep experience in therapeutic area analysis and strategic development, opportunity assessment, due diligence, and alignment of research, commercial and clinical strategies. My recent accomplishments include working intensively with CoStim Pharmaceuticals' executive team to prioritize and launch that company's Cancer Immunotherapeutics portfolio. More recently I embedded with X-Chem Inc to create X-Rx Discovery, an asset-cent...
Mots-clés
immunotherapy
oncology
ido
car-t cells
adoptive cell therapy
tumor microenvironment
tim3
nivolumab
ipilimumab
cancer
pd-1
tumors
tregs
lymphoma
leukemia
ctla4
immunotherapeutics
biologic
clinical trials
cd20
cd19
biotech
biotechnology
solid tumors
r&d
#miceareliars
hdac
beta catenin
tgf beta
checkpoint inhibitor
a2ar
sting
aletabio.com
impact(tm)
cellular therapy
car t cells
adoptive cellular therapy
colorectal cancer
hyaluronan
pancreatic cancer
csf1r
mdsc
tam
ovarian cancer
pembrilizumab
tgfbeta
lag3
tnfr
pembrilizumab
lag3
tgfbeta
tnfr
pembrilizumab
lag3
tgfbeta
tnfr
tnfr
lag3
pembrilizumab
pd-1 family
b7 family
Tout plus